Thus, in this model, the anti-tumour activity of anti-mCD27 is dependent on appropriate FcγR interaction, with engagement of activatory FcγR detrimental to therapy, likely as a result of depletion of CD8+ and effector CD4+ T cells. This evidence concerns the gene CD4 and neoplasm.